| WB | 咨询技术 | Human,Rat,Monkey |
| IF | 咨询技术 | Human,Rat,Monkey |
| IHC | 1/200 - 1/1000 | Human,Rat,Monkey |
| ICC | 技术咨询 | Human,Rat,Monkey |
| FCM | 1/200 - 1/400 | Human,Rat,Monkey |
| Elisa | 1/10000 | Human,Rat,Monkey |
| Aliases | AKT; PKB; RAC; CWS6; PRKBA; PKB-ALPHA; RAC-ALPHA |
| Entrez GeneID | 207 |
| clone | 1F7G2 |
| WB Predicted band size | 55.7kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Rat,Monkey |
| Immunogen | Purified recombinant fragment of human AKT1 (AA: 1-150) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是3条关于AKT1抗体的参考文献，按您的要求整理：
---
1. **文献名称**：*"Selective AKT1 Antibody Validation in Breast Cancer Progression"*
**作者**：Lee et al. (2021)
**摘要**：研究验证了一种高特异性AKT1抗体(克隆号C7E2)在乳腺癌组织中的检测能力，发现其在区分AKT1磷酸化(Ser473)与非活性状态中的敏感性，揭示了AKT1激活与肿瘤转移的相关性。
---
2. **文献名称**：*"Development of a Monoclonal Antibody Targeting AKT1 for Immunohistochemical Analysis in Colorectal Cancer"*
**作者**：Martinez-Ramos et al. (2019)
**摘要**：开发了一种新型AKT1单克隆抗体(克隆号5D3)，通过免疫组化(IHC)和Western blot验证其在结直肠癌组织中的特异性，证实AKT1高表达与患者预后不良显著相关。
---
3. **文献名称**：*"AKT1-Specific Antibody Screening for Functional Studies in Glioblastoma"*
**作者**：Chen & Wong (2020)
**摘要**：系统性比较了市售AKT1抗体的性能(包括Abcam#ab32505和CST#2938)，发现不同抗体在检测胶质母细胞瘤细胞中AKT1亚细胞定位(胞质/核)时的差异，提出抗体选择需结合实验目的。
---
4. **文献名称**：*"AKT1 Antibody-Based Therapeutic Targeting in Ovarian Cancer"*
**作者**：Gupta et al. (2018)
**摘要**：利用AKT1特异性抗体偶联纳米颗粒(Ab-AKT1-NP)靶向卵巢癌细胞，体外实验证明其能有效抑制AKT1信号通路并诱导凋亡，为抗体介导的靶向治疗提供新策略。
---
**备注**：以上文献为示例性内容，实际引用时需核对真实出版物信息。如需具体文献链接，可补充说明研究方向(如抗体开发/应用场景)。
The AKT1 antibody is a crucial tool for studying the AKT serine/threonine kinase 1. a key player in the PI3K-AKT-mTOR signaling pathway. AKT1. part of the AGC kinase family, regulates diverse cellular processes including proliferation, survival, metabolism, and apoptosis. Structurally, AKT1 contains a pleckstrin homology (PH) domain for membrane anchoring, a catalytic kinase domain, and a regulatory hydrophobic motif. Activation occurs via PI3K-generated PIP3. which recruits AKT1 to the plasma membrane, enabling phosphorylation at Thr308 (by PDK1) and Ser473 (by mTORC2). Dysregulation of AKT1 is implicated in cancers, diabetes, and neurological disorders.
AKT1 antibodies are widely used in Western blotting, immunohistochemistry, and flow cytometry to detect protein expression, phosphorylation status, and subcellular localization. They aid in exploring AKT1’s role in tumorigenesis, drug resistance, and therapeutic targeting. Commercial AKT1 antibodies are typically validated for specificity against conserved epitopes, with options targeting pan-AKT, phospho-specific sites, or isoform-specific regions (AKT1 vs. AKT2/AKT3). Researchers rely on these antibodies to dissect signaling mechanisms, assess pathway activation in clinical samples, and evaluate experimental therapies targeting AKT1. Proper validation using knockout controls or siRNA is essential due to potential cross-reactivity with homologous isoforms.
×
